

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for treating a B-cell, ~~T-cell, myeloid-cell, mast-cell, or plasma-cell~~ disorder in a horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat, comprising administering to the horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat having said disorder a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one anti-CD20, anti-CD74 or anti-HLA-DR antibody component ~~that is specific to a B-cell, T-cell, myeloid, mast cell, or plasma cell antigen or epitope in the horse, cattle, sheep, goat, llama, alpaca, pig, dog, or cat.~~
2. (Original) The method of claim 1, wherein said antibody component is a naked antibody.
3. (Original) The method of claim 1, wherein said antibody component is an immunoconjugate.
4. Canceled.
5. (Original) The method of claim 3, wherein said immunoconjugate is a radiolabeled immunoconjugate.
6. (Original) The method of claim 3, wherein said immunoconjugate comprises a cytokine.
7. (Original) The method of claim 3, wherein said immunoconjugate comprises a drug or toxin.
8. (Original) The method of claim 1, wherein said antibody component is part of a fusion protein.
9. (Currently amended) The method of claim 1, wherein said B-cell, ~~T-cell, myeloid, mast cell, or plasma-cell~~ disorder is a malignancy.
10. (Currently amended) The method of claim 1, wherein said B-cell, ~~T-cell, myeloid, mast cell, or plasma-cell~~ disorder is an autoimmune disease ~~and said antibody component is specific to a B-cell or T-cell.~~
- 11-13. Canceled.
14. (Original) The method of claim 1, additionally comprising administering a cytokine.
15. (Original) The method of claim 1, additionally comprising administering a chemotherapeutic agent.
16. (Currently amended) The method of claim 1, wherein said ~~domestic animal~~ therapeutic composition is administered to a companion animal.

17. (Original) The method of claim 16, wherein said companion animal is a dog or a cat.

18. (Currently amended) The method of claim 1, said ~~domestic animal~~ therapeutic composition is administered to a horse.

19-24. Canceled.

25. (Currently amended) The method of claim 49 1, wherein said therapeutic composition comprises a combination of two or more naked antibodies against different epitopes of the same antigen or against different antigens associated with one cell type.

26. (Currently amended) The method of claim 49 1, wherein said therapeutic composition comprises a combination of a naked antibody and a radiolabeled immunoconjugate.

27. (Currently amended) The method of claim 49 1, wherein said therapeutic composition comprises a combination of a naked antibody and a toxin iminunoconjugate.

28. (Original) The method of claim 27, wherein said toxin immunoconjugate comprises an RNase.

29. (Original) The method of claim 28, wherein said RNase is a recombinant RNase.

30-31. Canceled.

32. (Original) The method of claim 1, wherein the antibody component comprises a multispecific antibody.

33. (Original) The method of claim 1, wherein the antibody component comprises a bispecific antibody.

34. (Currently amended) The method of claim 33, wherein said antibody component comprises an arm that is specific for a low-molecular weight hapten and wherein a low-molecular weight hapten with an attached therapeutic agent is administered after the antibody component ~~that is specific to a B-cell, T-cell, myeloid, mast cell, or plasma cell antigen or epitope~~ is administered and has bound to the antigen or epitope.

35. (Original) The method of claim 34, wherein the therapeutic agent is a radionuclide.

36. (Original) The method of claim 34, wherein the therapeutic agent is a drug.

37. (Original) The method of claim 1, wherein said therapeutic composition comprises a combination of a chemotherapeutic agent and an antibody component labeled with a therapeutic radionuclide.

38-40. Canceled.

41. (Original) The method of claim 1, wherein said therapeutic composition comprises a combination of naked antibodies.

42. (Original) The method of claim 41, wherein said therapeutic composition comprises a fusion protein of said combination of antibodies.

43. (Original) The method of claim 1, wherein said therapeutic composition comprises a combination of naked antibodies and immunoconjugates.

44. (Currently amended) The method claim 1, wherein said therapeutic composition comprises a hybrid antibody that binds to more than one B-cell, T-cell, myeloid-cell, mast-cell or plasma-cell antigen.

45. Canceled.

46. (Original) The method of claim 1, additionally comprising administering radiation therapy.

47. Canceled.

48. (Original) The method of claim 1, additionally comprising administering an immunosuppressive agent.

49. (New) The method of claim 1, wherein the therapeutic composition comprises an anti-CD74 antibody.

50. (New) The method of claim 1, wherein the therapeutic composition comprises an anti-HLA-DR antibody.